NZ718153A - Stable polypeptides binding to human complement c5 - Google Patents
Stable polypeptides binding to human complement c5Info
- Publication number
- NZ718153A NZ718153A NZ718153A NZ71815314A NZ718153A NZ 718153 A NZ718153 A NZ 718153A NZ 718153 A NZ718153 A NZ 718153A NZ 71815314 A NZ71815314 A NZ 71815314A NZ 718153 A NZ718153 A NZ 718153A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- polypeptide
- amino acid
- compound
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1350986 | 2013-08-28 | ||
| PCT/EP2014/068282 WO2015028558A1 (en) | 2013-08-28 | 2014-08-28 | Stable polypeptides binding to human complement c5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ718153A true NZ718153A (en) | 2022-05-27 |
Family
ID=51539238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ718153A NZ718153A (en) | 2013-08-28 | 2014-08-28 | Stable polypeptides binding to human complement c5 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9994626B2 (enExample) |
| EP (2) | EP3811961B1 (enExample) |
| JP (2) | JP6767865B2 (enExample) |
| KR (1) | KR102446636B1 (enExample) |
| CN (1) | CN105658228B (enExample) |
| AU (1) | AU2014314222B2 (enExample) |
| BR (1) | BR112016003142A2 (enExample) |
| CA (1) | CA2926976C (enExample) |
| CY (1) | CY1123732T1 (enExample) |
| DK (1) | DK3038633T3 (enExample) |
| ES (1) | ES2842105T3 (enExample) |
| HR (1) | HRP20210013T1 (enExample) |
| HU (1) | HUE052613T2 (enExample) |
| IL (1) | IL244218A (enExample) |
| LT (1) | LT3038633T (enExample) |
| MX (1) | MX382140B (enExample) |
| MY (1) | MY173804A (enExample) |
| NZ (1) | NZ718153A (enExample) |
| PH (1) | PH12016500371A1 (enExample) |
| PL (1) | PL3038633T3 (enExample) |
| PT (1) | PT3038633T (enExample) |
| RS (1) | RS61347B1 (enExample) |
| RU (2) | RU2733897C2 (enExample) |
| SA (1) | SA516370622B1 (enExample) |
| SG (1) | SG11201602679VA (enExample) |
| SI (1) | SI3038633T1 (enExample) |
| SM (1) | SMT202100006T1 (enExample) |
| UA (1) | UA117933C2 (enExample) |
| WO (1) | WO2015028558A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102149028B1 (ko) | 2012-02-20 | 2020-08-27 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
| HRP20210013T1 (hr) * | 2013-08-28 | 2021-04-02 | Ipc Research, Llc | Stabilni polipeptidi koji se vezuju za ljudski komplement c5 |
| TR201911279T4 (tr) * | 2013-08-28 | 2019-08-21 | Affibody Ab | Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması. |
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| CN111201246B (zh) | 2017-07-11 | 2023-10-27 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
| MX2024005285A (es) * | 2021-11-01 | 2024-09-18 | Ipc Res Llc | Administracion de proteinas de union a c5. |
| WO2024227886A1 (en) | 2023-05-02 | 2024-11-07 | Mebrahtu Aman | Bispecific binding molecule |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| WO2002030985A2 (en) | 2000-10-10 | 2002-04-18 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| AU2002331601B2 (en) * | 2001-08-17 | 2006-04-13 | Tanox, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| WO2005023866A2 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
| SE0400274D0 (sv) * | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| AU2007223796B2 (en) * | 2006-03-08 | 2013-01-24 | Astellas Us Llc | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| WO2007106585A1 (en) * | 2006-03-15 | 2007-09-20 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| ES2346178T3 (es) | 2007-07-31 | 2015-11-02 | Affibody Ab | Nuevas composiciones, procedimientos y usos de unión de la albúmina |
| US9187535B2 (en) | 2007-12-19 | 2015-11-17 | Affibody Ab | Polypeptide derived from protein A and able to bind PDGF |
| EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| BRPI0916668B1 (pt) | 2008-08-05 | 2021-12-28 | Novartis Ag | Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| ES2540114T3 (es) * | 2010-07-09 | 2015-07-08 | Affibody Ab | Polipéptidos |
| KR102149028B1 (ko) | 2012-02-20 | 2020-08-27 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
| JP5980104B2 (ja) | 2012-11-22 | 2016-08-31 | 三菱電機株式会社 | 液晶表示装置の製造方法および液晶表示装置の製造システム |
| US9957330B2 (en) | 2012-12-19 | 2018-05-01 | Affibody Ab | Polypeptides |
| TR201911279T4 (tr) * | 2013-08-28 | 2019-08-21 | Affibody Ab | Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması. |
| HRP20210013T1 (hr) * | 2013-08-28 | 2021-04-02 | Ipc Research, Llc | Stabilni polipeptidi koji se vezuju za ljudski komplement c5 |
-
2014
- 2014-08-28 HR HRP20210013TT patent/HRP20210013T1/hr unknown
- 2014-08-28 SG SG11201602679VA patent/SG11201602679VA/en unknown
- 2014-08-28 ES ES14765883T patent/ES2842105T3/es active Active
- 2014-08-28 UA UAA201603124A patent/UA117933C2/uk unknown
- 2014-08-28 DK DK14765883.5T patent/DK3038633T3/da active
- 2014-08-28 KR KR1020167007498A patent/KR102446636B1/ko active Active
- 2014-08-28 HU HUE14765883A patent/HUE052613T2/hu unknown
- 2014-08-28 US US14/914,290 patent/US9994626B2/en active Active
- 2014-08-28 RS RS20210005A patent/RS61347B1/sr unknown
- 2014-08-28 EP EP20201264.7A patent/EP3811961B1/en active Active
- 2014-08-28 RU RU2016111115A patent/RU2733897C2/ru active
- 2014-08-28 SM SM20210006T patent/SMT202100006T1/it unknown
- 2014-08-28 RU RU2020128977A patent/RU2020128977A/ru unknown
- 2014-08-28 PL PL14765883T patent/PL3038633T3/pl unknown
- 2014-08-28 CN CN201480057470.XA patent/CN105658228B/zh active Active
- 2014-08-28 MY MYPI2016700583A patent/MY173804A/en unknown
- 2014-08-28 JP JP2016537298A patent/JP6767865B2/ja active Active
- 2014-08-28 LT LTEP14765883.5T patent/LT3038633T/lt unknown
- 2014-08-28 EP EP14765883.5A patent/EP3038633B1/en active Active
- 2014-08-28 CA CA2926976A patent/CA2926976C/en active Active
- 2014-08-28 PT PT147658835T patent/PT3038633T/pt unknown
- 2014-08-28 SI SI201431739T patent/SI3038633T1/sl unknown
- 2014-08-28 MX MX2016002397A patent/MX382140B/es unknown
- 2014-08-28 BR BR112016003142A patent/BR112016003142A2/pt not_active Application Discontinuation
- 2014-08-28 NZ NZ718153A patent/NZ718153A/en unknown
- 2014-08-28 WO PCT/EP2014/068282 patent/WO2015028558A1/en not_active Ceased
- 2014-08-28 AU AU2014314222A patent/AU2014314222B2/en active Active
-
2016
- 2016-02-22 IL IL244218A patent/IL244218A/en active IP Right Grant
- 2016-02-24 PH PH12016500371A patent/PH12016500371A1/en unknown
- 2016-02-25 SA SA516370622A patent/SA516370622B1/ar unknown
-
2020
- 2020-07-01 JP JP2020113725A patent/JP2020172505A/ja active Pending
- 2020-12-30 CY CY20201101229T patent/CY1123732T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9994626B2 (en) | Stable polypeptides binding to human complement C5 | |
| ES2346178T3 (es) | Nuevas composiciones, procedimientos y usos de unión de la albúmina | |
| JP6486908B2 (ja) | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 | |
| ES2306794T3 (es) | Moleculas de autoensamblaje. | |
| JP6590695B2 (ja) | アルブミン結合ポリペプチド | |
| KR102497083B1 (ko) | 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드 | |
| WO2017013136A1 (en) | Novel binding proteins based on di-ubiquitin muteins and methods for generation | |
| CN113785052B (zh) | 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途 | |
| Cachia et al. | Synthetic peptide vaccine development: measurement of polyclonal antibody affinity and cross‐reactivity using a new peptide capture and release system for surface plasmon resonance spectroscopy | |
| HK40050539A (en) | Stable polypeptides binding to human complement c5 | |
| HK40050539B (en) | Stable polypeptides binding to human complement c5 | |
| JP6818305B2 (ja) | 非天然型立体構造を形成した抗体に親和性を示すポリペプチド | |
| HK1225656B (en) | Stable polypeptides binding to human complement c5 | |
| BR112020018563A2 (pt) | Anticorpos de domínio único que se ligam à neurotoxina do tétano | |
| BR122023020080B1 (pt) | Polipeptídeos e compostos de ligação a c5 do complemento humano | |
| JP5645155B2 (ja) | 分子量マーカー及び分子量マーカーの作製方法 | |
| HK40064258B (zh) | 新重组二胺氧化酶及其治疗以过量组胺为特徵的疾病的用途 | |
| NZ716426B2 (en) | Binding polypeptides having a mutated scaffold | |
| EP3325515A1 (en) | Novel binding proteins based on di-ubiquitin muteins and methods for generation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: IPC RESEARCH, LLC, US Effective date: 20220309 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2024 BY CPA GLOBAL Effective date: 20230817 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240809 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250731 |